AI in neuroscience

A new milestone in digitl healthcare has been achieved in the neurotechnology sector with
AI. The BrainSpec’s AI software founded by Alex Zimmerman, is a digital platform which
aids the diagnostic process of brain disorders in a non-invasic manner, in other words its a
virtual brain biopsy! This AI-powered application uses data from non-invasice magnetic
resonance spectroscopy (MRS) scans to measure brain chemistry. This biological application,
reflects on the chemical composition and potential modifications in the metabolic pathwasy
in the brain tissue. So, it simply measures the chemical compounds and the intermediate
products of cellular metabolism (called metabolites) and diagnoses major brain disorders and
brain injuries and aids in subsequent tratments of schizophrenia, dementia, epilepsy, AD,
Parkinson’s disease, and traumatic brain injury. schizophrenia, dementia, epilepsy, AD,
Parkinson’s disease, and traumatic brain injury.

The John Hopkins university school of medicine, discovered through research in 2019, that
patients with mild cognitive impairment can be correlated to reduced levels of certain
neurmetabolites, such as glutamate and GABA. The national institute of health, US (NIH),
then disclosed that patients with mild cognitive impairment have an increased risk of
developing dementia and Alzheimer’s disease, as a follow up of the study. As said by
Raymond Y. Hung MD, PhD, division chief at Brigham and Women’s Hospital, “First, it
provides quantitative neurometabolite measurements that can be used to aid in monitoring
the changes in brain tumours that are undergoing therapy. The second strength is that it
automates the delivery of the MR spectroscopy results, reducing turn-around time from days
to minutes which is critical for the clinical care of patients.” This give’s use reliable and.
Credible insights about how the AI powered biotechnology aids the digitally the healthcare
system with brain chemistry assessments. Research studies like the above provide evidence
and justification for applications such as Brain Spec’s.

So, consequently, even The US Food and Drug Administration, FDA has also cleared Brain
Spec’s AI software (MRS platform), as the software showed increased degree of sensitivity
(85%) and specificity(90%), meaning high precision. This clearance means that the AI
powered software will be accessible to clinicians. Moreover, as it is the same equipment as
MRI, so positively, this platform can be implemented in the hospitals on the same MRI
scanners, being beneficial to the hospitals as this means reduced costs. This makes the
implementation of the software more accessible, affordable, and efficient with the time-
saving comprehensive technology, aiding the national healthcare system.

Written by Khyati Sharma

 Works Cited

"AI Uses Brain Chemistry for Precision Neuroscience." Psychology Today, 21 Dec. 2023,

www.psychologytoday.com/us/blog/the-future-brain/202312/ai-uses-brain-

chemistry-for-precision-neuroscience.

Barrie, Robert. "FDA Clears BrainSpec’s AI-powered MRS Platform." Medical Device

Network, 27 Nov. 2023, www.medicaldevice-network.com/news/fda-clear-

brainspecs-ai-powered-mrs-platform/?cf-view.

"BrainSpec AI Software Receives FDA Clearance for Noninvasive Brain Chemistry

Assessment." Practical Neurology, practicalneurology.com/news/brainspec-ai-

software-receives-fda-clearance-to-assist-in-diagnosis-of-neurologic-disorders-using-

mr-spectroscopy.